Figure 1From: Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatmentProfile of patient enrollment and discontinuations through 28 weeks of treatment.Back to article page